

Truenat[®] for Tuberculosis

Chip-based Real-Time PCR Test for MTB,
MTB Plus, MTB-RIF Dx and MTB-INH




An Archaic Disease, Still a Global Challenge

Every day, tuberculosis claims

3,400 lives,
approximately.

A curable bacterial disease dating back to 3000 BC—once called the “White Plague” in 18th-century Europe—TB remains one of the world’s deadliest infectious threats even today.

Glaring Global Diagnostic Gap*



(*as per 2023 data)


Cost Of Falling Through That Gap?

Permanent lung damage
—even after cure

High mortality among
PLHIV

Surge in drug-resistant
TB strains

Preventable deaths due
to missed diagnosis



Bridge the Gap with Truenat®

The WHO in 2021 recommended upfront molecular nucleic acid amplification tests (NAATs)—like Truenat®—over traditional smear microscopy for TB detection.

Truenat[®] Tuberculosis Assay Portfolio

Truenat[®] MTB

Detects *Mycobacterium tuberculosis* DNA in pulmonary and extrapulmonary specimens. Acts as the initial diagnostic test for TB detection per WHO guidelines

Target selection: *nrdB*, which codes ribonucleoside-diphosphate reductase, large subunit



Truenat[®] MTB Plus

Detects *Mycobacterium tuberculosis* DNA in pulmonary and extrapulmonary specimens. Acts as the initial diagnostic test for TB detection per WHO guidelines.

Target selection: *nrdZ* gene, which codes ribonucleoside-diphosphate reductase adenosyl cobalamin-dependent protein and the IS6110 gene sequence



Truenat[®] MTB RIF Dx

Identifies rifampicin resistance in TB-positive specimens — serving as a critical tool for RR-TB (rifampicin-resistant TB) diagnosis.

Target selection: RRDR region of the *rpoB* gene




Truenat[®] MTB INH

Aids in detection of isoniazid resistance, allowing for differentiation between mono- and multidrug-resistant TB.

Target selection: *inhA* and *katG* genes of *mycobacterium tuberculosis* genome

Lancet Study on the Impact of Truenat[®]

An independent study across clinics in Tanzania and Mozambique, published in The Lancet, showed the real-world impact of decentralising molecular TB testing with the Truenat[®] platform.



(as per 2025 data)

KEY FEATURES



<1 hour turnaround time



Reagent stability

Room temperature stable reagents



User-friendly

Requires minimal human resource training



Lyophilized, ready-to-use PCR reagents



Smart chip

Replete with batch-specific data



Minimal biosafety requirements

Can be used even in resource limited settings



MOLBIO DIAGNOSTICS LIMITED
L-46, Phase II D, Verna Industrial Estate,
Verna, Goa - 403 722, India



+91 832-2783267



sales@molbiodiagnostics.com



www.molbiodiagnostics.com



customersupport@molbiodiagnostics.com